with a bioreactor capacity of around 330,000 liters. The acquisition will boost Lonza’s (OTCPK:LZAGF) (OTCPK:LZAGY) large-scale biologics manufacturing capacity for mammalian therapies and ...

Lonza raised 2.07B CHF in additional debt but ... It is one of the world's largest biologics manufacturing sites, with a bioreactor capacity of 330,000 liters. The total consideration of 1.44B ...

BURLINGAME, CA, UNITED STATES, February 17, 2025 /EINPresswire / -- Latest Report, titled“Small Scale Bioreactors Market” Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032 ...

Acumen Pharmaceuticals has entered a strategic partnership with Swiss contract manufacturer Lonza to further the development of sabirnetug (ACU193), a potential treatment for Alzheimer's disease (AD).

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The extended relationship builds ...